INTRODUCTION: A patient pathway is an evidence-based tool that details the phases of care with the aim of increasing the effectiveness and efficiency of patient care. We describe diagnostic and treatment pathways and related overall survival (OS) of non-small cell lung cancer patients. METHODS: This was a longitudinal, historical descriptive cohort study based on administrative claim data, spanning from 2017 to 2022. The index date was determined by the first bronchoscopy with lung biopsy (BX) followed by histopathological (HP) examination, alongside the presence of the International Classification of Diseases 10th revision diagnosis code C34. Incident patients aged ≥18 without prior malignancy. Pharmacotherapies (PHT), including chemotherapy (PHT_CT), precision therapy (PHT_IOTT), as well as surgery (SX) and radiotherapy (RT), were investigated associated with OS. A presence of multidisciplinary team (MDT) and treatment at a Complex Oncological Center (COC) with high-load experience was considered. RESULTS: We analysed 5819 patient pathways. Less than half (45.6%) of patients had MDT reported within a median of 20 days. Of the 4417 patients treated, 30% underwent more than one BX, 47.7% received PHT_CT, 25.9% underwent SX, 16.4% underwent RT and 9.08% PHT_IOTT. Early initiation of treatment within 4 weeks from BX was identified in 21% of SX patients, 30% of patients treated with PHT_CT and 23% of RT patients. The centralisation of care in COCs primarily concerned SX and PHT_IOTT, while 33% of patients indicated to PHT_CT were treated elsewhere. The median OS reached approximately 16 months in the overall population, 21 months in the verified treated cohort and 13 months in patients treated with PHT_CT, while it was not reached in patients treated with SX. We observed a positive association between patient prognosis and treatment centralisation in COCs. CONCLUSIONS: This methodology can be implemented as a technical infrastructure to fulfil the organisation and quality evaluation routines in cancer care, largely based on administrative data.

Center for Pneumology and Interventional Bronchology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Biomedical Technology Czech Technical University Prague Faculty of Biomedical Engineering Praha Czech Republic

Department of Oncology General University Hospital Prague Praha Czech Republic

Department of Respiratory Medicine and Tuberculosis Brno University Hospital Brno Czech Republic

Department of Respiratory Medicine University Hospital Hradec Králové Hradec Králové Czech Republic

Institute of Health Information and Statistics of the Czech Republic Praha Czech Republic

Pulmonary Department Charles University Faculty of Medicine in Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi: 10.1002/ijc.29210. PubMed DOI

Molina JR, Yang P, Cassivi SD, et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc. 2008;83:584–94. doi: 10.1016/S0025-6196(11)60735-0. PubMed DOI PMC

Francisci S, Minicozzi P, Pierannunzio D, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2242–53. doi: 10.1016/j.ejca.2015.07.033. PubMed DOI

Borilova S, Dusek L, Jakubikova L, et al. Lung Cancer in the Czech Republic. J Thorac Oncol. 2023;18:271–7. doi: 10.1016/j.jtho.2022.11.023. PubMed DOI

Liu T, Chen Z, Dang J, et al. The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis. PLoS ONE. 2018;13:e0210001. doi: 10.1371/journal.pone.0210001. PubMed DOI PMC

Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7:170070. doi: 10.1098/rsob.170070. PubMed DOI PMC

Lu S, Kong H, Hou Y, et al. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer (Auckl) 2018;123:44–51. doi: 10.1016/j.lungcan.2018.06.027. PubMed DOI

Morgensztern D, Ng SH, Gao F, et al. Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey. J Thorac Oncol. 2010;5:29–33. doi: 10.1097/JTO.0b013e3181c5920c. PubMed DOI

Zhang Y, Simoff MJ, Ost D, et al. Understanding the patient journey to diagnosis of lung cancer. BMC Cancer. 2021;21:402. doi: 10.1186/s12885-021-08067-1. PubMed DOI PMC

Lechtzin N, Rubin HR, White P, Jr, et al. Patient satisfaction with bronchoscopy. Am J Respir Crit Care Med. 2002;166:1326–31. doi: 10.1164/rccm.200203-231OC. PubMed DOI

Karewicz A, Faber K, Karon K, et al. Evaluation of patients’ satisfaction with bronchoscopy procedure. PLoS One. 2022;17:e0274377. doi: 10.1371/journal.pone.0274377. PubMed DOI PMC

Benn BS, Parikh M, Tsau PH, et al. Using a Dedicated Interventional Pulmonology Practice Decreases Wait Time Before Treatment Initiation for New Lung Cancer Diagnoses. Lung. 2019;197:249–55. doi: 10.1007/s00408-019-00207-6. PubMed DOI

Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 2016;42:56–72. doi: 10.1016/j.ctrv.2015.11.007. PubMed DOI

Coory M, Gkolia P, Yang IA, et al. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer (Auckl) 2008;60:14–21. doi: 10.1016/j.lungcan.2008.01.008. PubMed DOI

Lüchtenborg M, Riaz SP, Coupland VH, et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol. 2013;31:3141–6. doi: 10.1200/JCO.2013.49.0219. PubMed DOI

Brunelli A, Falcoz PE, D’Amico T, et al. European guidelines on structure and qualification of general thoracic surgery. Eur J Cardiothorac Surg. 2014;45:779–86. doi: 10.1093/ejcts/ezu016. PubMed DOI

Lambert L, Janouskova L, Novak M, et al. Early detection of lung cancer in Czech high-risk asymptomatic individuals (ELEGANCE) Medicine (Abingdon) 2021;100:e23878. doi: 10.1097/MD.0000000000023878. PubMed DOI PMC

Menasalvas Ruiz E, Tuñas JM, Bermejo G, et al. Profiling Lung Cancer Patients Using Electronic Health Records. J Med Syst. 2018;42:126. doi: 10.1007/s10916-018-0975-9. PubMed DOI

Snyder CF, Wu AW, Miller RS, et al. The role of informatics in promoting patient-centered care. Cancer J. 2011;17:211–8. doi: 10.1097/PPO.0b013e318225ff89. PubMed DOI PMC

Houser SH, Colquitt S, Clements K, et al. The impact of electronic health record usage on cancer registry systems in Alabama. Perspectives in Health Information Management / AHIMA, American Health Information Management Association. 2012;9 PubMed PMC

IPAAC. https://www.ipaac.eu n.d. Available.

R Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2024. https://www.R-project.org/ Available.

Otty Z, Brown A, Sabesan S, et al. Optimal Care Pathways for People with Lung Cancer- a Scoping Review of the Literature. Int J Integr Care. 2020;20:14. doi: 10.5334/ijic.5438. PubMed DOI PMC

Ansar A, Lewis V, McDonald CF, et al. Defining timeliness in care for patients with lung cancer: a scoping review. BMJ Open. 2022;12:e056895. doi: 10.1136/bmjopen-2021-056895. PubMed DOI PMC

van Hoeve JC, Vernooij RWM, Fiander M, et al. Effects of oncological care pathways in primary and secondary care on patient, professional and health systems outcomes: a systematic review and meta-analysis. Syst Rev. 2020;9:246. doi: 10.1186/s13643-020-01498-0. PubMed DOI PMC

Blum TG, Morgan RL, Durieux V, et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J. 2023;61:2103201. doi: 10.1183/13993003.03201-2021. PubMed DOI

Jackson H, Minot GR. The Medical Care of the Cancer Patient. Am J Cancer. 1931;15:6–11.

Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. Thorax. 2009;64:749–56. doi: 10.1136/thx.2008.109330. PubMed DOI

Gould MK, Ghaus SJ, Olsson JK, et al. Timeliness of care in veterans with non-small cell lung cancer. Chest. 2008;133:1167–73. doi: 10.1378/chest.07-2654. PubMed DOI

Banks KC, Dusendang JR, Schmittdiel JA, et al. Association of Surgical Timing with Outcomes in Early Stage Lung Cancer. World j surg. 2023;47:1323–32. doi: 10.1007/s00268-023-06913-w. PubMed DOI PMC

NICE . NICE Guideline. 2022. Suspected cancer recognition and referral suspected cancer recognition and referral overview overview.

Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20:1–146. doi: 10.3310/hta20400. PubMed DOI PMC

Tanner NT, Silvestri GA. What’s in a Number? When It Comes to Pulmonary Nodules, It’s All About the Number. Am J Respir Crit Care Med. 2015;192:1149–50. doi: 10.1164/rccm.201508-1665ED. PubMed DOI

Gould MK, Tang T, Liu I-LA, et al. Recent Trends in the Identification of Incidental Pulmonary Nodules. Am J Respir Crit Care Med. 2015;192:1208–14. doi: 10.1164/rccm.201505-0990OC. PubMed DOI